Supernus Pharmaceuticals filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company focused on central nervous system diseases. Recent Form 8-K reports cover operating results, conference-call related earnings releases, material definitive agreements, executive compensation arrangements, and other material events tied to the company's CNS product portfolio and corporate obligations.
Proxy materials describe annual meeting voting matters, director elections, advisory executive compensation votes, auditor ratification, and equity incentive plan amendments. The filings also identify the company's common stock structure, exchange listing, shareholder voting mechanics, governance practices, and capital-structure disclosures.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/23/2025. He acquired 47,940 shares by exercising employee stock options with an exercise price of $12.98 (options vested in installments beginning 03/01/2017; expiration 03/01/2026). On the same date he sold 29,513 shares in multiple transactions at a weighted average price of $47.23. The acquisition was made pursuant to a 10b5-1 trading plan adopted 11/14/2024. Following these transactions his direct beneficial ownership is reported as 1,140,883 shares, and he also holds 1,005,600 shares indirectly through the KBT Trust. The form was signed by an attorney-in-fact on 09/24/2025.
Jack A. Khattar, President, CEO and a director of Supernus Pharmaceuticals (SUPN), reported transactions on 09/22/2025. He exercised 27,060 employee stock options with an exercise price of $12.98 (resulting from options granted earlier) and acquired 27,060 shares. On the same date he sold 16,587 shares at a weighted-average price of $47.02. Following these transactions the filing shows 1,122,456 shares beneficially owned directly and 1,005,600 shares indirectly through the KBT Trust. The exercise and acquisition were reported as made pursuant to a 10b5-1 trading plan adopted November 14, 2024. The Form 4 was signed by an attorney-in-fact on 09/23/2025.
Form 144 filing for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 29,513 shares of common stock through Morgan Stanley Smith Barney on 09/23/2025 to be executed on the NASDAQ. The shares were acquired and paid for on 09/23/2025 by exercise of stock options, with payment in cash. The filing also lists multiple Rule 10b5-1 sales by Jack A. Khattar over August–September 2025, showing several transactions and gross proceeds. The notice includes the seller's representation regarding absence of undisclosed material information.
Form 144 filed for Supernus Pharmaceuticals, Inc. (SUPN) reports a proposed sale of 16,587 common shares with an aggregate market value of $763,665.48, representing securities listed on NASDAQ. The filing shows the shares were acquired and paid for on 09/22/2025 through exercise of stock options and paid in cash. The issuer’s outstanding common shares are reported as 56,073,088. The filing also discloses a series of prior 10b5-1 sales by JACK A KHATTAR over the past three months totaling 239,200 shares for gross proceeds of $10,414,682.10. The filer certifies no undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals, reported option exercise and share sales on 09/08/2025. He exercised 8,074 employee stock options with an exercise price of $25.30 per share (options vesting began 02/24/2018 and expire 02/24/2027), resulting in 8,074 common shares issued. On the same date he sold 6,322 shares at a weighted average price of $46.29 per share (sales occurred at prices between $46.00 and $46.40). Following these transactions he beneficially owned 1,111,983 common shares. The exercise and sale were made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
Insider transactions by Jack A. Khattar, President and CEO of Supernus Pharmaceuticals (SUPN): On 09/05/2025 Mr. Khattar exercised 73,176 employee stock options with a $25.30 exercise price and acquired those shares. The same day he sold 55,578 shares at a weighted average price of $46.01 (sales ranged $46.00–$46.09). After these transactions he beneficially owned 1,110,231 shares directly and 1,005,600 shares indirectly through the KBT Trust. The exercise was reported under a 10b5-1 plan adopted November 14, 2024.
Supernus Pharmaceuticals insider activity notice reports a proposed sale of 6,322 common shares acquired and to be sold on 09/08/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the trade is planned on NASDAQ with an aggregate market value of $290,812. The filing also discloses multiple prior 10b5-1 sales by Jack A Khattar totaling 232,878 shares during Aug–Sep 2025, generating gross proceeds shown in the table. The filer represents no undisclosed material adverse information and certifies compliance with Rule 144 and 10b5-1 representations.
Supernus Pharmaceuticals reported an insider notice to sell common stock following an option exercise. The filer plans to sell 55,578 shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $2,524,908.54 and an approximate sale date of 09/05/2025. The shares were acquired and paid for in cash on 09/05/2025 via exercise of stock options from the issuer. The filing also discloses multiple 10b5-1 sales by Jack A Khattar in August 2025 totaling 170,300 shares with gross proceeds shown across transactions. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Insider transactions by Jack A. Khattar at Supernus Pharmaceuticals (SUPN) show option exercises and share sales completed under a 10b5-1 plan. On 08/27/2025 and 08/28/2025 Mr. Khattar acquired 17,195 and 38,779 shares by exercising employee stock options at an exercise price of $12.98 per share. He also sold 10,650 shares on 08/27/2025 at a weighted average price of $45.05 and 24,150 shares on 08/28/2025 at a weighted average price of $45.12. After these transactions his direct beneficial ownership is reported at 1,092,633 shares, with an additional 1,005,600 shares indirectly held by the KBT Trust. The Form 4 notes the 10b5-1 trading plan was adopted on November 14, 2024.
Charles W. Newhall III, a director of Supernus Pharmaceuticals, Inc. (SUPN), sold 3,588 shares of the company's common stock on 08/27/2025 under a pre-existing Rule 10b5-1 trading plan. The sales were executed at a weighted average price of $45.01 per share, with transaction prices in the range $45.00 to $45.04. After the reported dispositions, the reporting person beneficially owned 129,644 shares, reported as a direct holding. The filing includes a statement that the reporting person will provide detailed per-price sale quantities on request and notes the 10b5-1 plan was adopted March 3, 2025.